US2007161085A1PendingUtilityA1

Methods of Producing Influenza Vaccine Compositions

59
Assignee: MEDLMMUNE VACCINES INCPriority: Feb 25, 2003Filed: Jan 30, 2007Published: Jul 12, 2007
Est. expiryFeb 25, 2023(expired)· nominal 20-yr term from priority
Inventors:George TragerGeorge KembleRichard SchwartzHarshvardhan MehtaVu Truong-LeZhongying ChenAlfred A. PanEric I-Fu TsaoChiaoyin WangLuisa YeePalani Balu
A61P 31/12A61P 31/16A61P 37/04C12N 2760/16151A61K 2039/525B01D 61/145A61K 35/76A61K 39/145C12N 2760/16251A61K 47/183B01D 61/147C12N 2760/16134C12N 7/00C12N 2760/16234A61K 47/26A61K 47/42A61K 47/02A61K 2039/5254A61K 39/12
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.

Claims

exact text as granted — not AI-modified
1 - 67 . (canceled)  
     
     
         68 . A live influenza virus composition, wherein the composition comprises, from about 5% to about 10% sucrose, about 1% to about 5% arginine, and from about 1% to about 4% gelatin, wherein the composition when stored from about 2° C. to about 8° C. exhibits less than or equal to 1.0 log potency loss in 12 months or less than or equal to 0.080 log potency loss per month.  
     
     
         69 . The live influenza virus composition of  claim 68 , wherein the composition comprises from about 1% to about 2% arginine.  
     
     
         70 . The live influenza virus composition of  claim 68 , wherein the influenza virus composition comprises about 1% gelatin.  
     
     
         71 . The live influenza virus composition of  claim 68 , wherein the composition comprises from about 7% to about 10% sucrose.  
     
     
         72 . The live influenza virus composition of  claim 68 , wherein the composition further comprises from about 5 mM to about 200 mM potassium phosphate buffer.  
     
     
         73 . The live influenza virus composition of  claim 72 , wherein the potassium phosphate buffer is at pH 7.2.  
     
     
         74 . The live influenza virus composition of  claim 72 , wherein the composition comprises about 100 mM potassium phosphate buffer.  
     
     
         75 . The influenza virus composition of  claim 72 , wherein the composition comprises from about 10 mM to about 12 mM potassium phosphate buffer.  
     
     
         76 . The live influenza virus composition of  claim 68 , wherein the composition has a pH of 7.2.  
     
     
         77 . The live influenza virus composition of  claim 68 , wherein the composition comprises from about 10% to about 60% normal allantoic fluid (NAF).  
     
     
         78 . The influenza virus composition of  claim 68 , wherein the composition comprises less then about 5% NAF.  
     
     
         79 . The live influenza virus composition of  claim 68 , wherein the composition does not comprise EDTA.  
     
     
         80 . The live influenza virus composition of  claim 68 , wherein the influenza virus is cold adapted.  
     
     
         81 . The live influenza virus composition of  claim 68 , wherein the potency is measured in fluorescent focus units.  
     
     
         82 . The live influenza virus composition of  claim 68 , wherein the composition when stored at about 4° C. exhibits less than or equal to 1.0 log potency loss in 12 months or less than or equal to 0.080 log potency loss per month.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.